The multifaceted NF-kB: are there still prospects ... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

The multifaceted NF-kB: are there still prospects of its inhibition for clinical intervention in pediatric central nervous system tumors?

Full text
Author(s):
Medeiros, Mariana [1] ; Candido, Marina Ferreira [1] ; Valera, Elvis Terci [2] ; Brassesco, Maria Sol [3]
Total Authors: 4
Affiliation:
[1] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Cell Biol, Ribeirao Preto, SP - Brazil
[2] Univ Sao Paulo, Ribeirao Preto Med Sch, Dept Pediat, Ribeirao Preto, SP - Brazil
[3] Univ Sao Paulo, FFCLRP USP, Fac Philosophy Sci & Letters Ribeirao Preto, Dept Biol, Av Bandeirantes 3900, BR-14040901 Ribeirao Preto, SP - Brazil
Total Affiliations: 3
Document type: Review article
Source: CELLULAR AND MOLECULAR LIFE SCIENCES; v. 78, n. 17-18 JUL 2021.
Web of Science Citations: 0
Abstract

Despite advances in the understanding of the molecular mechanisms underlying the basic biology and pathogenesis of pediatric central nervous system (CNS) malignancies, patients still have an extremely unfavorable prognosis. Over the years, a plethora of natural and synthetic compounds has emerged for the pharmacologic intervention of the NF-kB pathway, one of the most frequently dysregulated signaling cascades in human cancer with key roles in cell growth, survival, and therapy resistance. Here, we provide a review about the state-of-the-art concerning the dysregulation of this hub transcription factor in the most prevalent pediatric CNS tumors: glioma, medulloblastoma, and ependymoma. Moreover, we compile the available literature on the anti-proliferative effects of varied NF-kB inhibitors acting alone or in combination with other therapies in vitro, in vivo, and clinical trials. As the wealth of basic research data continues to accumulate, recognizing NF-kB as a therapeutic target may provide important insights to treat these diseases, hopefully contributing to increase cure rates and lower side effects related to therapy. (AU)

FAPESP's process: 10/16652-9 - NF-kB inhibition in glioblastoma: in vitro and in vivo effects of DHMEQ in tumor chemoresistance, invasion and progression
Grantee:María Sol Brassesco Annichini
Support Opportunities: Scholarships in Brazil - Young Researchers
FAPESP's process: 10/50635-4 - NF-Kb inhibition in glioblastoma: in vitro and in vivo effects of DHMEQ in tumor chemoresistence, invasion and progression
Grantee:María Sol Brassesco Annichini
Support Opportunities: Research Grants - Young Investigators Grants